ClinicalTrials.gg
CompletedNCT02232087Updated Jun 15, 2022Results posted

Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate

A Phase 1 interventional study of Salmeterol and fluticasone propionate in Healthy, sponsored by Kindeva Drug Delivery. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-15.

Sponsored by Kindeva Drug Delivery · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to test the body's response to several doses of two different inhalation products in healthy volunteers.

Read the detailed description

Healthy subjects will be enrolled and will receive 2, 6, and 12 inhalations from both the test and reference pMDI products according to a six-period cross-over design. Electrocardiograms (ECGs) and plasma potassium and glucose levels will be measured pre-dose and over 6 hours post-dose.

02

Conditions studied

  • Healthy

Keywords

  • long-acting beta agonist (LABA)
  • corticosteroid
  • pMDI
  • inhaler
03

In context

Lead sponsor

Kindeva Drug Delivery is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Volunteer
  • Willing and able to give
  • Willing to withhold all alcoholic beverages for 48 hours and all xanthine- containing foods and beverages for 24 hours prior to reporting to clinic
  • Male and female subjects aged 18 to 55 years (inclusive)
  • Subjects must agree to use an adequate method of from admission through 12 weeks after last administration

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of abnormalities or disease or chronic respiratory disorders
  • Any presence or history of a clinically significant allergy including any adverse reaction to study drug
  • History of drug or alcohol abuse within the past 2 years
  • Smoked tobacco within the past 6 months or have a history of more than 10- pack years (number of packs smoked per day x number of years smoked)
  • Donation or loss of greater than 400 mL of blood within the previous 3 months
  • Have received any prescription medication within 4 weeks or medication within 12 weeks of study (exception: are permitted)
  • Have received any non-prescription medication within 14 days prior to dosing (exception: paracetamol use within 2 days)
  • Upper respiratory tract infection (excluding otitis media) within 14 days of the first study day, or lower respiratory tract infection within the last 3 months
  • If female, nursing, lactating or pregnant
  • Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
  • Surgery scheduled during the study or within 3 weeks after last dose
  • History of familial long syndrome or history of sudden death in family members aged \< 30 years
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    test product A

    salmeterol and fluticasone propionate, 2 puffs

    Drug: Salmeterol · Drug: fluticasone propionate

  • Active comparator
    reference product D

    salmeterol and fluticasone propionate, 2 puffs

    Drug: Salmeterol · Drug: fluticasone propionate

  • Experimental
    test product B

    salmeterol and fluticasone propionate, 6 puffs

    Drug: Salmeterol · Drug: fluticasone propionate

  • Active comparator
    reference product E

    salmeterol and fluticasone propionate, 6 puffs

    Drug: Salmeterol · Drug: fluticasone propionate

  • Experimental
    test product C

    salmeterol and fluticasone propionate, 12 puffs

    Drug: Salmeterol · Drug: fluticasone propionate

  • Active comparator
    reference product F

    salmeterol and fluticasone propionate, 12 puffs

    Drug: Salmeterol · Drug: fluticasone propionate

Interventions

  • A, D 2 puffs; B, E 6 puffs; C, F 12 puffs

    Also known as: Sirdupla, Seretide Evohaler

  • A, D 2 puffs; B, E 6 puffs; C, F 12 puffs

    Also known as: Sirdupla, Seretide Evohaler

06

What researchers measure

Primary outcomes

  1. Relative Potency Max Heart Rate

    Selection of steepest part of dose response curve for Relative Potency: 6 and 12 inhalation dose pairs. Slope of B and C line compared with slope of E and F to obtain relative potency value. Two inhalation dose not utilized as not on steepest part of curve.

    Time frame: Baseline, up to 6 hrs

  2. Relative Potency QTcB Interval

    Selection of steepest part of dose response curve for Relative Potency: 2 and 6 inhalation dose pairs. Slope of A and B line compared with slope of D and E to obtain relative potency value. Twelve inhalation dose not utilized as not on steepest part of curve.

    Time frame: Baseline up to 6 hrs

Secondary outcomes

  1. Max Heart Rate

    max heart rate at the 2, 6, or 12 inhalations dose, assessed at multiple times over 6 hours

    Time frame: Baseline through 6 hours

  2. Plasma Potassium Level

    maximum plasma levels of potassium at 2, 6 or 12 inhalations dose inhalations dose, assessed a multiple times over 6 hours.

    Time frame: baseline through 6 hours

  3. Max Plasma Glucose Level

    maximum levels of glucose at the 2, 6 or 12 inhalations dose, assessed at multiple times over 6 hours.

    Time frame: baseline through 6 hours

  4. Max QTcB

    For each dose, the 95% CIs for the mean difference for the test product versus the reference product were calculated.

    Time frame: Baseline through 6 hours

07

Results

Posted Nov 2, 2020
Limitations and caveats
There are no limitations or caveats.

Participant flow

Recruitment began 07 July 2014

Participant flow — Overall Study
MilestoneSequence 1 (A, F, B, E, C, D)Sequence 2 (B, A, C, F, D, E)Sequence 3 (C, B, D, A, E, F)Sequence 4 (D, C, E, B, F, A)Sequence 5 (E, D, F, C, A, B)Sequence 6 (F, E, A, D, B, C )
Started9108889
Completed788776
Not completed220113
Withdrew: Withdrawal by subject200001
Withdrew: Poor inhalation technique010002
Withdrew: Protocol stop criteria010100
Withdrew: Adverse event000010

Outcome measures

PrimaryRelative Potency Max Heart Rate

Selection of steepest part of dose response curve for Relative Potency: 6 and 12 inhalation dose pairs. Slope of B and C line compared with slope of E and F to obtain relative potency value. Two inhalation dose not utilized as not on steepest part of curve.

Time frame:
Baseline, up to 6 hrs
Reported as:
Number · unitless
Relative Potency Max Heart Rate
unitlessTest B and C vs Reference E and F
Relative Potency Max Heart Rate0.8619 (0.7209 to 1.00)
Statistical analysis
  • Test B and C vs Reference E and F · ANOVA · p = >0.10 (test for parallelism of dose response lines) · Odds ratio, log: 1.00 · 90% CI 0.67 to 1.50Test is the numerator
PrimaryRelative Potency QTcB Interval

Selection of steepest part of dose response curve for Relative Potency: 2 and 6 inhalation dose pairs. Slope of A and B line compared with slope of D and E to obtain relative potency value. Twelve inhalation dose not utilized as not on steepest part of curve.

Time frame:
Baseline up to 6 hrs
Reported as:
Number · unitless
Relative Potency QTcB Interval
unitlessTest A and B vs Reference D and E
Relative Potency QTcB Interval1.0760 (0.8206 to 1.4238)
Statistical analysis
  • Test A and B vs Reference D and E · ANOVA · p = >0.10 (test for parallelism of dose response lines) · Odds ratio, log: 1.00 · 90% CI 0.67 to 1.50Test is the numerator
SecondaryMax Heart Rate

max heart rate at the 2, 6, or 12 inhalations dose, assessed at multiple times over 6 hours

Time frame:
Baseline through 6 hours
Reported as:
Mean · bpm
Max Heart Rate
bpmTest Product AReference Product DTest Product BReference Product ETest Product CReference Product F
Max Heart Rate65.1 ± 10.965.5 ± 10.168.9 ± 11.069.9 ± 12.275.3 ± 13.376.8 ± 14.8
Statistical analysis
  • Test Product A vs Reference Product D · ANOVA · p = 0.55 (Comparability demonstrated for p\>0.05) · Mean difference (final values): 0 · 95% CI -2.5 to 1.4Comparability confirmed if confidence interval includes zero.
  • Test Product B vs Reference Product E · ANOVA · p = 0.53 (Comparability demonstrated for p\>0.05) · Mean difference (final values): 1.0 · 95% CI -2.5 to 1.3Comparability confirmed if confidence interval includes zero.
  • Test Product C vs Reference Product F · ANOVA · p = 0.011 (Comparability demonstrated for p\>0.05) · Mean difference (final values): 1.00 · 95% CI -2.5 to 1.3Comparability confirmed if confidence interval includes zero.
SecondaryPlasma Potassium Level

maximum plasma levels of potassium at 2, 6 or 12 inhalations dose inhalations dose, assessed a multiple times over 6 hours.

Time frame:
baseline through 6 hours
Reported as:
Mean · mmol/L
Plasma Potassium Level
mmol/LTest Product AReference Product DTest Product BReference Product ETest Product CReference Product F
Plasma Potassium Level3.82 ± 0.193.78 ± 0.163.76 ± 0.203.75 ± 0.193.63 ± 0.243.61 ± 0.26
Statistical analysis
  • Test Product A vs Reference Product D · ANOVA · p = 0.26 (Comparability demonstrated for p\>0.05) · Mean difference (final values): 0 · 95% CI -0.03 to 0.10Comparability confirmed if confidence interval includes zero.
  • Test Product B vs Reference Product E · ANOVA · p = 0.93 (Comparability demonstrated for p\>0.05) · Mean difference (final values): 0 · 95% CI -0.06 to 0.06Comparability confirmed if confidence interval includes zero.
  • Test Product C vs Reference Product F · ANOVA · p = 0.48 (Comparability demonstrated for p\>0.05) · Mean difference (final values): 0 · 95% CI -0.04 to 0.08Comparability confirmed if confidence interval includes zero.
SecondaryMax Plasma Glucose Level

maximum levels of glucose at the 2, 6 or 12 inhalations dose, assessed at multiple times over 6 hours.

Time frame:
baseline through 6 hours
Reported as:
Mean · mmol/L
Max Plasma Glucose Level
mmol/LTest Product AReference Product DTest Product BReference Product ETest Product CReference Product F
Max Plasma Glucose Level5.31 ± 0.495.31 ± 0.405.53 ± 0.655.62 ± 0.545.88 ± 0.665.98 ± 0.65
Statistical analysis
  • Test Product A vs Reference Product D · ANOVA · p = 0.93 (Comparability demonstrated for p\>0.05) · Mean difference (final values): 0Comparability confirmed if confidence interval includes zero.
  • Test Product B vs Reference Product E · ANOVA · p = 0.42 (Comparability demonstrated for p\>0.05) · Mean difference (final values): 0 · 95% CI -0.224 to 0.093Comparability confirmed if confidence interval includes zero.
  • Test Product C vs Reference Product F · ANOVA · p = 0.078 (Comparability demonstrated for p\>0.05) · Mean difference (final values): 0 · 95% CI -0.302 to 0.016Comparability confirmed if confidence interval includes zero.
SecondaryMax QTcB

For each dose, the 95% CIs for the mean difference for the test product versus the reference product were calculated.

Time frame:
Baseline through 6 hours
Reported as:
Mean · ms
Max QTcB
msTest Product AReference Product DTest Product BReference Product ETest Product DReference Product F
Max QTcB422.3 ± 22.4422.1 ± 23.7430.0 ± 23.1430.2 ± 21.4441.0 ± 20.5444.0 ± 26.7
Statistical analysis
  • Test Product A vs Reference Product D · ANOVA · p = 0.71 (Comparability demonstrated for p\>0.05) · Mean difference (final values): 0 · 95% CI -3.9 to 5.7Comparability confirmed if confidence interval includes zero.
  • Test Product B vs Reference Product E · ANOVA · p = 1.00 (Comparability demonstrated for p\>0.05) · Mean difference (final values): 0 · 95% CI -4.7 to 4.7Comparability confirmed if confidence interval includes zero.
  • Test Product D vs Reference Product F · ANOVA · p = 0.016 (Comparability demonstrated for p\>0.05) · Mean difference (final values): -2 · 95% CI -10.6 to -1.1Comparability confirmed if confidence interval includes zero.

Adverse events

Collected over Adverse events were collected for up to 2 months for each subject. The duration of the clinical phase of the study was 4 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test Product A4/49 (8.2%)0/49 (0%)4/49 (8.2%)
Test Product B5/48 (10.4%)0/48 (0%)5/48 (10.4%)
Test Product C11/47 (23.4%)0/47 (0%)11/47 (23.4%)
Reference Product D5/47 (10.6%)0/47 (0%)5/47 (10.6%)
Reference Product E4/48 (8.3%)0/48 (0%)4/48 (8.3%)
Referencet Product F8/50 (16%)0/50 (0%)8/50 (16%)
Most frequent other events
Showing 10 of 23
Most frequent other events
EventTest Product ATest Product BTest Product CReference Product DReference Product EReferencet Product F
headacheNervous system disorders2/492/484/473/474/484/50
DizzinessNervous system disorders0/490/484/470/470/480/50
NervousnessPsychiatric disorders0/490/481/470/471/483/50
Feeling HotGeneral disorders0/490/480/470/471/482/50
PalpitationsCardiac disorders0/490/481/470/470/482/50
tremorNervous system disorders0/490/480/470/470/482/50
FlushingVascular disorders0/490/480/470/470/482/50
VomitingGastrointestinal disorders0/490/480/471/470/480/50
Feeling ColdGeneral disorders0/490/481/470/470/480/50
ECG QT prolongedInvestigations0/490/481/470/470/481/50

Baseline characteristics

all subjects who received at least one test and one reference product for same dose

Age, Continuous
Age, Continuous(years)All Subjects
Mean33.5 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)All Subjects
Female23
Male29
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Subjects
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American1
White46
More than one race0
Unknown or Not Reported4
Region of Enrollment
Region of Enrollment(participants)All Subjects
United Kingdom52
BMI
BMI(kg/m2)All Subjects
Mean23.6 ± 1.8
forced expiratory volume at one second
forced expiratory volume at one second(% predicted normal)All Subjects
Mean101.19 ± 10.74
08

Study locations

1 site
  • Quotient Clinical Ltd
    Ruddington, Nottingham NG11 6JS, United Kingdom
09

References and documents

Publications

  • Harrison LI, Sessions V, Wiggenhorn CJ, Chalmers D, Leung P, Efthimiou J. Comparison of systemic pharmacodynamic effects of two combination pressurized metered dose inhalers that deliver salmeterol and fluticasone propionate. Br J Clin Pharmacol. 2017 Nov;83(11):2377-2385. doi: 10.1111/bcp.13349. Epub 2017 Aug 1. PubMed 28626983 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Oct 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2020, 6 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2014
First posted
Sep 4, 2014
Start
Jul 2014
Primary completionActual
Oct 2014
CompletionActual
Dec 2014
Results first posted
Nov 2, 2020
Last update
Jun 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02232087
Lead sponsor
Kindeva Drug Delivery
Responsible party
Sponsor
First posted
Sep 4, 2014
Start date
Jul 2014
Primary completion
Oct 2014
Completion
Dec 2014
Results posted
Nov 2, 2020
Last update
Jun 15, 2022

Study contacts

Pui Leung, MD
principal investigator · Quotient Clinical Ltd

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Salmeterol Xinafoate · Fluticasone

Start the discussion